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osting by EAbstract Leishmania donovani, the causative agent of visceral leishmaniasis, is transmitted by sand
ﬂies and replicates intracellularly in their mammalian host cells. The emergence of drug-resistant
strains has hampered efforts to control the spread of the disease worldwide. Forty-four 1,3,4-thia-
diazole derivatives and related compounds were tested in vitro for possible anti-leishmanial activity
against the promastigotes of L. donovani. Micromolar concentrations of these agents were used to
study the inhibition of multiplication of L. donovani promastigotes. Seven compounds were identi-
ﬁed with potential antigrowth agents of the parasite. Compound 4a was the most active at 50 lM
followed by compound 3a. These compounds could prove useful as a future alternative for the con-
trol of visceral leishmaniasis.
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lsevier1. Introduction
Leishmania parasites have a life cycle that includes an extracel-
lular ﬂagellated promastigote stage, and an obligatory intracel-
lular, non-motile amastigote stage. The promastigotes are
transmitted to mammalian hosts through the bite of sand ﬂies
and are rapidly transformed into non-ﬂagellated amastigotes
within mononuclear phagocytes.
Visceral leishmaniasis is one of the three clinical syndromes
(visceral, cutaneous, and mucocutaneous leishmaniasis)
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Figure 1 Chemical structures of 1,3,4-thiadiazole derivatives and
related compounds which showed activity against L. donovani.
228 A. Al-Qahtani et al.produced by Leishmania infection. Visceral leishmaniasis is
caused by three related species or subspecies (Leishmania dono-
vani, L.d. infantum, L.d. chagasi), which make up the L. dono-
vani complex. These protozoan parasites produce a systemic
and life-threatening infection by infecting reticuloendothelial
cells and macrophages in all organs. More than 90% of vis-
ceral leishmaniasis cases occur in Bangladesh, Brazil, India
and Sudan. It is a zoonotic disease using different reservoirs
and sand ﬂy vectors in different parts of the world. Infection
may be subclinical but clinical disease is fatal if untreated
(Lainson and Shaw, 1987; Rioux et al., 1990; Herwaldt, 1999).
Currently, the treatment of choice for visceral leishmaniasis
is pentavalent antimonial compounds in the form of sodium
stibogluconate and N-methylglucamine antimoniate. Cases of
visceral leishmaniasis may also be treated by other agents such
as pentamidine and paromomycin. Recently, other new poten-
tially powerful drugs such as liposomal amphotericin B have
been introduced, and the advantage is that lipsome-encapsu-
lated drugs are more effective and less toxic. Several new com-
pounds also show promising effects (Davis and Kedzierski,
2005; Singh and Sivakumar, 2004; Berman, 2005; Santos
et al., 2008).
Within the last decade, the incidence of Leishmania infec-
tion has increased signiﬁcantly due mainly to the high cost
of drugs and emergence of immunosuppressive illnesses like
AIDS (Paredes et al., 2003; Wolday et al., 1999; Pratlong
et al., 2003). Drug resistance has been a major problem with
about 25% of strains becoming resistant to antimonial treat-
ment (Abdo et al., 2003; Faraut-Gambarelli et al., 1997; Hen-
derson et al., 1992; Arevalo et al., 2001). These facts highlight
the urgent need to develop new and more effective drugs to
combat visceral leishmaniasis.
In our previous report (Al-Qahtani et al., 2005), pyrazolo-
quinoline derivatives were evaluated as leishmanicidal agents
and a few of these compounds showed good potential activity
against L. donovani. Furthermore, several recent reports have
pointed out to the importance of 1,3,4-thiadiazole derivatives
as potential treatment against the cutaneous form of leishman-
iasis caused by L. major (Poorrajab et al., 2008; Behrouzi-
Fardmoghadam et al., 2008). In this study, we tested a new
family of 1,3,4-thiadiazoles and related compounds for their
effect on the growth of L. donovani promastigotes. Few com-
pounds showed an inhibitory effect on growth of the parasite.2. Materials and methods
2.1. Compounds
Forty-four 1,3,4-thiadiazole analogs were synthesized accord-
ing to the method described by Chaaban et al. (2007). Seven
of these compounds were found to possess antileishmanial
activity. The chemical structures of these seven compounds
are presented in Fig. 1.
2.2. Parasites
Leishmania donovani strain DD8 was a kind gift from Dr. May
Al-Jaser, Zoology Department, College of Science, King Saud
University, Riyadh, Saudi Arabia. The parasites were cultured
in Medium 199 (Invitrogen, Bethesda, MD, USA) supple-
mented with 10% fetal bovine serum and penicillin and strep-tomycin added at a concentration of 100 IU/ml and 100 lg/ml,
respectively. All incubations were carried on at 26 C. Stock
solutions of these compounds were made in dimethyl sulfoxide
(DMSO) (Merck, Germany) and stored in the dark at 20 C.
2.3. Assay for antileishmanial activity
After 5 days of incubation, the promastigote culture was cen-
trifuged at 2000g for 10 min at room temperature. The pellet
was suspended in Schneider’s insect medium (Sigma Chemical
Company, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum. The number of promastigotes was adjusted to
1 · 107 cell/ml. Ninety-six well plates (Nunc, Denmark) were
inoculated with 50 ll/well of the parasite culture. Stock solu-
tions of 1,3,4-thiadiazole compounds were dissolved in Schei-
neder’s medium and 50 ll of different concentrations were
added to the culture in triplicate. Maximum concentration of
DMSO in promastigote cultures (with or without the thiadia-
zole derivates) did not exceed 0.4%, which is within a safe limit
for the parasites. After 2 days of incubation, wells in 96-well
plates were examined microscopically for the motility of prom-
Inhibition of growth of Leishmania donovani 229astigotes. Growth of the para-sites was monitored using tetra-
zolium (MTS) colorimetric assay purchased from Promega,
Madison WI, USA (Cory et al., 1991). Plates were incubated
at 37 C for 4–5 h and the absorbance was read at 490 nm
wavelength according to manufacturer’s instructions. Ampho-
tericin B at a concentration of 50 lM was used in the test pro-
tocol as a control.
2.4. Statistical analysis
Absorbance values from the test and control wells were ana-
lyzed using two-sample t-test. All p-values 60.005 were consid-
ered signiﬁcant.
3. Results and discussion
Forty-four new 1,3,4-thiadiazole analogs were tested for their
antileishmanial activity. These compounds were previously
tested for their antimicrobial activity (unpublished results).
Out of the forty-four compounds tested, only seven showed
strong antileishmanial activity and their antiproliferative ef-
fects were comparable, at equimolar concentration, to that
of the positive control, e.g. amphotericin B, a potent antileish-
manial agent (Table 1).
Compounds 1a, 2a, 3a, 3b and 4a showed very promising
antileishmanial effects, even at concentrations as low as
50 lM. Compound 4a was the most active at low concentra-
tion (50 lM). However, at higher concentrations, compound
3a showed the strongest activity against the growth of the par-
asite. Compounds 1a, 2a and 3b were also effective, especially
at higher concentrations (i.e., 200 lM and 400 lM). Two com-
pounds 1b and 1c also affected growth of the parasites at
(400 lM) but at 50 lM, they were completely ineffective. The
microscopic observation revealed that promastigotes were
non-motile when incubated with the test compounds while
the controls (with no compound) were actively motile.
Some 1,3,4-thiadiazole derivatives have received recogni-
tion because they have been shown to possess potential antimi-
crobial and antiviral agents (Gadad et al., 2000; Kristanida
et al., 2002; Invidiata et al., 1996). A few of these compounds
have been described to be very potent in inhibiting reverse
transcriptase in HIV-1 (Hanasaki et al., 1995).
It is evident that there is a growing interest in 1,3,4-thia-
diazole derivatives as potential antileishmanial compounds.Table 1 Effect of 1,3,4-thiadiazole analogs and related compounds
400 lM
Control (untreated) 0.859 ± 0.016
Control (amphotericin B-treated cells) –
Compound 1a 0.330 ±
Compound 1b 0.290 ±
Compound 1c 0.303 ±
Compound 2a 0.324 ±
Compound 3a 0.260 ±
Compound 3b 0.370 ±
Compound 4a 0.449 ±
Parasites were seeded in complete medium containing indicated concentra
MTS assay. Each number represents the mean and standard deviation of
All other values are statistically signiﬁcant compared to the untreated co
** Not signiﬁcant.Foroumadi et al. showed that thiadiazole derivatives have
leishmanicidal activity against L. major (Foroumadi et al.,
2005a,b). Also, da Silva et al. tested a group of similar com-
pounds against L. amazonensis and observed effective killing
of the parasites (da Silva et al., 2002). The effect observed
could be related to modulation and/or inhibition of G pro-
tein-coupled receptors in the parasite as it has been shown
that some thiadiazole analogs are strong modulators of such
cell molecules (Fawzi et al., 2001). Leishmania was shown to
possess G protein-coupled receptors similar to those found
in mammalian cells (Cassel et al., 1991; Fu et al., 1998).
One possible explanation for the inhibitory effect of these
compounds on the parasite may be attributed to their inter-
ference with the redox potential in the cells (Li et al., 2003).
There are several similar available compounds shown to be
effective against the growth of Trypanosoma cruzi (Maya
et al., 2003) and T. brucei (Bouteille et al., 1995). It was sug-
gested these compounds might exert antiproliferative effects
through production of nitro radical anions (Bouteille
et al., 1995). However, we would like to suggest that there
could be other mechanisms by which these thiadiazole ana-
logs work, since compounds described in this study do not
have nitro groups. The antileishmanial effect of these com-
pounds could be attributed to the functional groups which
are capable of formation of free radicals such as 1,4-dime-
thoxyphenyl group (i.e., compounds 1a, 1b, 1c and 2a) or
1,4-dihydroxyphenyl group (i.e. compounds 3a, 3b, and
4a). These compounds could permeate through the cell plas-
ma membrane and damage nucleic acids and/or proteins in-
side the cell (Enanga et al., 2003). Alternatively, they might
damage proteins or other molecules essential for the growth
of the parasite located at the extracellular space of the plas-
ma membrane such as adenosine receptors (Hansen et al.,
1986; van Muijlwijk-Koezen et al., 2001). Furthermore,
1,3,4-thiadiazole analogs might exert their effect through
modiﬁcation of sulfhydryl groups of cysteine residues in
some essential enzymes and other important proteins as they
have been shown to be strong sulfhydryl modifying agents
(Goblyos et al., 2005).
In conclusion, 1,3,4-thiadiazole derivatives have been
shown to possess a promising antileishmanial effect in vitro.
However, these compounds have to be thoroughly appraised
for their acute toxicity and genotoxicity. Furthermore, their ef-
fect in vivo in experimental animals should be performed toon growth of L. donovani promastigotes.
200 lM 100 lM 50 lM
– – 0.381 ± 0.057
0.020 0.337 ± 0.010 0.430 ± 0.030 0.610 ± 0.070
0.020 0.380 ± 0.002 0.680 ± 0.04 1.060 ± 0.050**
0.003 0.402 ± 0.010 0.690 ± 0.040 1.070 ± .0400**
0.004 0.360 ± 0.006 0.580 ± 0.010 0.630 ± 0.030
0.008 0.270 ± 0.003 0.340 ± 0.010 0.538 ± 0.050
0.014 0.330 ± 0.014 0.590 ± 0.070 0.670 ± 0.080
0.032 0.424 ± 0.031 0.426 ± 0.013 0.495 ± 0.050
tion of each compound and the viability of cells was estimated using
three reading.
ntrol when calculated at a 95% conﬁdence level. P-value 60.005.
230 A. Al-Qahtani et al.draw a meaningful conclusion. Both lines of experiments are
underway in our laboratory.References
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